Description

I help companies navigate M&A transactions and make better investment decisions through rigorous financial analysis. With buy-side experience at a leading PE-backed pharma platform (Astorg portfolio), I bring hands-on deal execution skills from screening through IC-ready deliverables.

What I deliver:

- DCF and trading comps valuations with scenario/sensitivity analysis

- CIM reviews, strategic fit assessments, and No-Go recommendations

- Working capital analysis (DSO/DIO/DPO), EV-to-equity bridges, and pricing guardrails

- Investment memos and IC-ready materials for senior decision-makers

- Market and supply/demand assessments for target industries

My background spans corporate development, alternative investment valuation (IFRS 13/IPEV), and financial analysis across Pharma/CDMO, PE, and financial services. I hold an MSc in Finance (Aarhus University), am pursuing an MBA at Frankfurt School, and have passed CFA Level II.

Tools: Excel (advanced, VBA/macros), PowerPoint, Bloomberg, S&P Capital IQ, PitchBook, Python.

Industry field of expertise

Languages

Danish
Native or bilingual
English
Fluent
German
Fluent
Swedish
Conversational
Norwegian
Conversational

Workplace preferences

Can work on-site

Frankfurt am Main (up to 50km)

CordenPharma (Astorg Portfolio)
Corporate Development and M&A, MBA Associate
PHARMACEUTICALS INDUSTRY
August 2025 - Today (10 months)
Plankstadt, BW, Germany
• • Led the buy-side valuation workstream. Built DCFs and trading comps from CIM inputs and ran sensitivities across WACC, margin ramp, and CapEx phasing to set valuation ranges and pricing guardrails (incl. a preliminary walk-away price).
• •Assessed business fundamentals and strategic fit early to identify deal-breakers and prioritize diligence on the right targets.
• • Built working-capital benchmarks by calculating and benchmarking DSO/DIO/DPO to derive a normalized NWC for purchase price adjustments. Built the EV-to-equity bridge (net debt and NWC).
• • Built a global peptide API supply/demand assessment across pharma/biotech and CDMOs. Modeled capacity ramp by site and over time (scale-up and ramp-up) to map bottlenecks and capacity gaps across demand scenarios.

Selected deal experience (buy-side, confidential)
• • Peptide-focused CDMO (Pre-LOI): built the initial valuation (DCF + trading comps). Normalized base/downside cases using achievable output (incl. yield/waste), margin ramp, CapEx ramp/normalization, and normalized NWC. Prepared an IC/internal approval pack with valuation range (base/downside) and a data/diligence request list for management sign-off.
• • Diversified CDMO platform (No-Go): conducted a CIM review and fit assessment. Identified strategic scope misalignment (non-core modality) and material complexity risks across a multi-site operating model and QA harmonization. Delivered a documented No-Go recommendation.
Due Diligence Business Valuation M&A Financial Modeling
The Halal Shack
Corporate Development Consultant
RESTAURANTS AND FOOD SERVICE
May 2024 - June 2025 (1 year and 1 month)
Dallas, TX, USA
• • Built DCF-based business cases for market entry and site expansion supporting ~USD 12m in CapEx planning.
• • Led demographic analysis and pre-opening diligence across 20+ sites, enabling 8 on-time launches. Developed financial projections, assessed site-level P&L economics, and presented investment recommendations to founders and stakeholders.
Due Diligence Business Plan Development Business Valuation Financial Modeling Investor documents
BNY Mellon
Senior Analyst, Valuation & Due Diligence, Alternative Investments
BANKING AND INSURANCE
August 2021 - April 2024 (2 years and 8 months)
Copenhagen, Denmark
• • Performed independent fair value analysis of 30+ alternative funds and illiquid investments under IFRS 13 and IPEV principles. Validated investment manager valuations using market data, comparable assets, and model-based valuations (cashflow- or rate-based, depending on the instrument).
• • Reviewed key assumptions (discount rates/spreads, terminal value and liquidity adjustments such as DLOM) and challenged outliers with evidence requirements for changes in reported fair value.
• • Delivered valuation conclusions and driver attribution for internal stakeholders and client-facing materials.
Business Valuation Financial Modeling